"It makes perfect sense to have started manufacturing already. What wouldn't make sense is to not start it when they know they'll need it whether they partner up or go it alone with grant funds. No trials without drugs."
Haven't they pre started B for sachets for OM, and one other indication in another form (than sachets) first (sorry, forget which one)?
What makes you think this is true, and shall "pan out"?
News 
Market Data 
Discover 
AI
